Unlike AML, myelofibrosis is not cell-autonomous. Malignant cells damage the bone marrow and spleen via cytokines. This chronic environmental damage explains slow recovery post-transplant and highlights the need for therapies that address this influence, not just the cancer cells themselves.
Clinicians should avoid delaying myelofibrosis treatment, especially in asymptomatic patients with massive splenomegaly. Waiting can lead to a downward spiral of complications like thrombocytopenia, which limits future therapeutic options. The greater clinical error is inaction and waiting too long to intervene.
When treating frail, elderly myelofibrosis patients with ruxolitinib, the focus should be on the speed of dose escalation. While starting low is common, clinicians must titrate up every few weeks, not months, to reach the target therapeutic level and avoid undertreatment.
Abruptly stopping JAK inhibitors can trigger a potentially fatal SIRS-like syndrome from a cytokine storm. Clinicians must taper the dose. If an abrupt stop is necessary (e.g., for a procedure), bridging the patient with prednisone is a critical and effective strategy to prevent this severe withdrawal reaction.
For a transplant-eligible myelofibrosis patient with a large spleen, using an upfront combination therapy is a compelling strategy. Reducing spleen size pre-transplant is known to improve engraftment, making this a clear clinical scenario for more aggressive initial treatment to optimize outcomes.
Clinicians should interpret anemia in myelofibrosis patients on JAK inhibitors based on its timing. Anemia in the first 16 weeks is an expected on-target effect. In contrast, new anemia in a patient on a stable dose is a warning sign that may indicate disease progression, warranting further investigation.
Unlike other driver mutations, mutant calreticulin (CALR) is expressed on the cell surface while the wild-type protein is not. This creates an ideal scenario for mutation-specific immunotherapies like antibodies, bispecifics, and CAR-T cells, which can attack cancer cells with high precision.
Myelofibrosis trials for anemia often fail to meet endpoints because their primary measure, transfusion burden, is not objective. The decision to transfuse is a subjective clinical judgment without a universal numerical trigger. This introduces variability that can mask a drug's true efficacy, complicating data interpretation.